Prokaryotics Licenses Gram-Negative Antibiotic Potentiator From Northern Antibiotics

Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics

Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.

Prokaryotics Announces Licensing Agreement with Northern Antibiotics for Novel Gram-negative Antibiotic Potentiator

UNION, N.J., June 26, 2025 /PRNewswire/ -- Prokaryotics Inc., a privately-held biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, announced today that it has entered into a licensing agreement with Northern Antibiotics on June 4, 2025.